Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: A European organization for research and treatment of cancer

被引:48
作者
Lortholary, O
Ascioglu, S
Moreau, P
Herbrecht, R
Marinus, A
Casassus, P
De Pauw, B
Denning, DW
机构
[1] Univ Manchester, N Manchester Gen Hosp, Dept Infect Dis & Trop Med, Manchester M8 6RL, Lancs, England
[2] Univ Paris 13, Hop Avicenne, Ctr Rech Pathol Infect & Trop, Serv Med Interne, Bobigny, France
[3] CHRU, Hotel Dieu, Hematol Serv, Nantes, France
[4] CHU Hautepierre, Serv Onco Hematol, F-67098 Strasbourg, France
[5] European Org Res & Treatment Canc, Invas Fungal Infect Cooperat Grp, Ctr Data, Brussels, Belgium
[6] Univ Nijmegen, Dept Hematol, Nijmegen, Netherlands
关键词
D O I
10.1086/313592
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We report the occurrence of invasive aspergillosis (ZA) in nonallografted patients with multiple myeloma (MM) who were treated at hematology or oncology centers in Europe during 1984-1996. Thirty-one cases met the criteria for definitive (21 [68%]) or probable (10 [32%]) IA, Of these cases, 23 (74%) were reported during 1992-1996, Twenty-nine cases (94%) occurred in patients with Durie-Salmon stage 3 MM, and 2 (6%) occurred in patients with Durie-Salmon stage 2 MM, The median time between MM and IA diagnoses was 8 months (range, 1-75 months). Sixteen patients (51%) had a neutrophil count less than or equal to 500/mm(3) for a median duration of 19 days (range, 10-37 days). Fourteen patients (45%) had recently received corticosteroid therapy, and 11 (36%), high doses of melphalan, Twenty-eight patients had primary pulmonary IA, and 3 had primary sinus IA, Forty-dye percent of patients were considered to have died of IA, IA occurs as a potentially lethal opportunistic infection in intensively treated nonallografted patients with myeloma.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 39 条
[1]   Standard therapy versus autologous transplantation in multiple myeloma [J].
Attal, M ;
Harousseau, JL .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (01) :133-&
[2]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[3]   HIGH-DOSE MELPHALAN AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR REFRACTORY MULTIPLE-MYELOMA [J].
BARLOGIE, B ;
JAGANNATH, S ;
DIXON, DO ;
CHESON, B ;
SMALLWOOD, L ;
HENDRICKSON, A ;
PURVIS, JD ;
BONNEM, E ;
ALEXANIAN, R .
BLOOD, 1990, 76 (04) :677-680
[4]  
BARLOGIE B, 1988, BLOOD, V72, P2015
[5]   Multiple myeloma [J].
Bataille, R ;
Harousseau, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1657-1664
[6]  
BENNETT JE, 1995, MANDELL DOUGLAS BENN, P2306
[7]   Allogeneic stem cell transplantation for multiple myeloma [J].
Bensinger, WI ;
Buckner, CD ;
Gahrton, G .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (01) :147-&
[8]   Diagnosis, prognosis, and standard treatment of multiple myeloma [J].
Boccadoro, M ;
Pileri, A .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (01) :111-&
[9]  
BUNCH C, 1988, NEW ENGL J MED, V319, P902
[10]  
Chronic Leukemia-Myeloma Task Force. National Cancer Institute, 1973, CANC CHEMOTHER REP, V4, P145